Literature DB >> 8961965

Five years of tamoxifen--or more?

R Peto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8961965     DOI： 10.1093/jnci/88.24.1791

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

Review 2.  Adjuvant tamoxifen: how long before we know how long?

Authors:  D Rea; C Poole; R Gray
Journal:  BMJ       Date:  1998-05-16

3.  Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality.

Authors:  R G Blanks; S M Moss; C E McGahan; M J Quinn; P J Babb
Journal:  BMJ       Date:  2000-09-16

Review 4.  The changing global patterns of female breast cancer incidence and mortality.

Authors:  Freddie Bray; Peter McCarron; D Maxwell Parkin
Journal:  Breast Cancer Res       Date:  2004-08-26       Impact factor: 6.466

5.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

6.  Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.

Authors:  S Gupta; M Singh; Amish Vora; G Babu; M Walia; V Nautial; R Saha; B K Smruti; J B Sharma; R Koul; Purvish M Parikh; S Aggarwal
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.